Pediatric brain tumor research depends on seeing more than one piece of the story at a time. A tumor’s molecular profile matters, for example. So do diagnosis, treatment history, imaging, biospecimen information, and clinical outcomes. But too often, those details live in separate systems, formats, and workflows.
That fragmentation limits what researchers can ask and how quickly they can move from data access to discovery.
The Children’s Brain Tumor Network (CBTN) is working to change that with CBTN Curated | LGG-BRAF, a first-of-its-kind low-grade glioma data product now available in CAVATICA. Built around the CBTN M3 approach, this resource connects multimodal, multiomic, and multidisciplinary data into one research-ready cohort designed to help researchers immediately dive in to study pediatric brain tumors with greater depth and precision.
The cohort brings together clinical, genomic, imaging, and biospecimen data from approximately 200 pediatric low-grade glioma patients with BRAF mutations. Researchers can begin exploring the dataset within minutes through the free, cloud-based CAVATICA analytics tool.
But the significance of the project is not only in its access. It’s what becomes possible when complex data are prepared, connected, and delivered for discovery from the start.
“This is more than a dataset,” said Dr. David Higgins, CBTN Informatics Program Manager. “The goal was to create something researchers can trust and actually use right away.”
Moving Beyond Fragmented Data
Large amounts of data do not automatically become usable evidence. Clinical records need review across institutions. Genetic data must be standardized. Imaging must be matched to patient histories while protecting privacy. Missing information must be identified and resolved.
The CBTN Curated | LGG-BRAF data product was built to reduce that barrier. The cohort underwent extensive review and validation by the multi-institutional CBTN Clinical Data Working Group and collaborating teams across the network. Clinical records were reviewed patient by patient, discrepancies were resolved, and standards were harmonized across contributing institutions.
What makes this effort the first of its kind is not one data type alone. It is the combination of disease-specific precision, longitudinal depth, multimodal integration, and immediate cloud-based usability. The data product does not simply gather files in one place. It connects key parts of the patient journey so researchers can examine how clinical history, molecular findings, imaging, and biospecimens relate over time.
“We need as much information as possible to understand these tumors,” Higgins said. “When you can connect these different types of data, you begin creating opportunities to ask much more meaningful questions.”
That connected structure allows researchers to investigate how molecular findings, imaging patterns, treatments, and outcomes relate across patients. For a disease area shaped by tumor behavior, treatment response, and long-term progression, that longitudinal view matters.
Creating a New Model for Precision Research
The decision to begin with low-grade glioma (LGG) was intentional. LGG is the most common pediatric brain tumor within CBTN, providing both a substantial cohort size and strong clinical relevance. The focus on BRAF-mutated tumors adds research value, since BRAF alterations are among the most important molecular drivers in pediatric LGG.
In CAVATICA, researchers can review cohort summaries, participant information, inclusion criteria, available data types, and supporting documentation in one place, with direct connections to imaging and specimen-related resources. That design helps researchers move from access to analysis efficiently while preserving the rigor needed for meaningful interpretation.
For Higgins, one of the most important aspects of the effort is the ability to represent patients more completely.
“We’re not sharing isolated files,” Higgins said. “We’re bringing together the broader story of each patient’s care journey, from diagnosis and surgery to treatment, imaging, and molecular profiling.”
CBTN sees this launch as part of a larger shift in how pediatric cancer data can be prepared and delivered for research. Instead of asking investigators to assemble fragmented pieces on their own, the CBTN Curated | LGG-BRAF data product offers a more complete starting point for discovery.
The goal is not simply to make pediatric brain tumor data easier to find. It’s to help researchers ask stronger questions, study tumor behavior with more context, and accelerate progress toward more precise approaches for children with cancer.
Researchers can explore the CBTN Curated | LGG-BRAF data product by creating a free account in CAVATICA and accessing the cohort directly through the platform.
